IL143632A0 - Pharmaceutical compositions containing lactobacillus - Google Patents
Pharmaceutical compositions containing lactobacillusInfo
- Publication number
- IL143632A0 IL143632A0 IL14363299A IL14363299A IL143632A0 IL 143632 A0 IL143632 A0 IL 143632A0 IL 14363299 A IL14363299 A IL 14363299A IL 14363299 A IL14363299 A IL 14363299A IL 143632 A0 IL143632 A0 IL 143632A0
- Authority
- IL
- Israel
- Prior art keywords
- pharmaceutical compositions
- compositions containing
- containing lactobacillus
- compositions
- lactobacillus
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Biochemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention provides methods and compositions for the oral administration of Lactobacillus and/or other probiotic organisms, such as Bifidobacterium, for establishment and maintenance of a healthy urogenital flora. The invention also provides methods and compositions to reduce the risk of disease.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11196598P | 1998-12-11 | 1998-12-11 | |
PCT/CA1999/001182 WO2000035465A2 (en) | 1998-12-11 | 1999-12-10 | Oral administration of lactobacillus for the treatment and prevention of urogenital infection |
Publications (1)
Publication Number | Publication Date |
---|---|
IL143632A0 true IL143632A0 (en) | 2002-04-21 |
Family
ID=22341404
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL14363299A IL143632A0 (en) | 1998-12-11 | 1999-12-10 | Pharmaceutical compositions containing lactobacillus |
Country Status (15)
Country | Link |
---|---|
US (1) | US6479051B1 (en) |
EP (1) | EP1137423B1 (en) |
JP (1) | JP2003522731A (en) |
KR (1) | KR20010101171A (en) |
AT (1) | ATE290391T1 (en) |
AU (1) | AU1543400A (en) |
BR (1) | BR9916062A (en) |
CA (1) | CA2354054C (en) |
DE (1) | DE69924141D1 (en) |
ID (1) | ID30071A (en) |
IL (1) | IL143632A0 (en) |
NZ (1) | NZ512275A (en) |
PL (1) | PL348973A1 (en) |
TR (1) | TR200101699T2 (en) |
WO (1) | WO2000035465A2 (en) |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000071138A2 (en) * | 1999-05-25 | 2000-11-30 | Gregor Reid | Oral administration of lactobacillus for the maintenance of health in women |
US20020044926A1 (en) * | 1999-12-10 | 2002-04-18 | Gregor Reid | Oral administration of lactobacillus for the treatment and prevention of urogenital infection |
EP1312667B1 (en) | 2000-08-25 | 2008-12-31 | Wakamoto Pharmaceutical Co., Ltd. | Probiotic products containing L. salivarius strain |
SE521022C2 (en) * | 2001-09-20 | 2003-09-23 | Ellen Ab | Lactic acid producing bacteria for use as probiotic organisms in the human vagina |
DE60143616D1 (en) | 2000-10-06 | 2011-01-20 | Oreal | USE OF PROBIOTIC MILKY ACID-PRODUCING BACTERIA FOR THE PROTECTION OF THE SKIN AGAINST UV-INDUCED ALLERGIC REACTIONS AND INFLAMMATORY DISEASES OR IMMUNOSUPPRESSION |
IL156490A0 (en) * | 2000-12-18 | 2004-01-04 | Probiohealth | Probiotic compounds derived from lactobacillus casei strain ke01 |
IL157071A0 (en) * | 2001-02-06 | 2004-02-08 | Nestle Sa | Endotoxine binding by lactic acid bacteria and bifidobacteria |
EE04580B1 (en) * | 2001-06-29 | 2006-02-15 | Tartu �likool | Microorganism strain Lactobacillus fermentum ME-3 as an antimicrobial and antioxidant probiotic |
US7479294B2 (en) * | 2001-07-23 | 2009-01-20 | The Procter & Gamble Company | System and method for on-line mixing and application of surface coating compositions for food products |
US20070098784A1 (en) * | 2001-09-28 | 2007-05-03 | Nutraceutix, Inc. | Delivery system for biological component |
DK1429802T3 (en) * | 2001-09-28 | 2013-02-18 | Tntgamble Inc | Biological component supply system |
WO2003082306A1 (en) * | 2002-03-28 | 2003-10-09 | Gregor Reid | Lactobacillus iners for the enhancement of urogenital health |
US20050100531A1 (en) * | 2002-06-13 | 2005-05-12 | John Bienenstock | Probiotic therapies |
AU2004204751A1 (en) * | 2003-01-09 | 2004-07-29 | The Trustees Of The University Of Pennsylvania | Compositions, methods and kits for enhancing the immunogenicity of a bacterial vaccine vector |
US20050100559A1 (en) * | 2003-11-07 | 2005-05-12 | The Procter & Gamble Company | Stabilized compositions comprising a probiotic |
GB0410785D0 (en) * | 2004-05-14 | 2004-06-16 | Glycologic Ltd | Improved prebiotic |
US7955834B2 (en) * | 2004-06-03 | 2011-06-07 | Biogaia Ab | Method for improved breast milk feeding to reduce the risk of allergy |
US20060062742A1 (en) * | 2004-09-21 | 2006-03-23 | The Procter & Gamble Company | Compositions for reduction of human malodor |
US20060229244A1 (en) * | 2004-09-27 | 2006-10-12 | Robert Dorit | Engineered bacteriocins and bacteriocin combinations and methods for treating bacterial based infections |
WO2006045347A1 (en) * | 2004-10-22 | 2006-05-04 | Medinova Ag | Lactobacillus helveticus strain useful in the treatment or prevention of infections caused by urogenital pathogens |
WO2006045474A1 (en) * | 2004-10-22 | 2006-05-04 | Medinova Ag | Lactic acid bacteria strains useful against gastrointestinal pathogens and compositions containing same |
BRPI0610609A2 (en) * | 2005-04-15 | 2010-07-06 | Univ North Carolina State | methods and compositions for modulating bacterial adhesion and stress tolerance |
US20070082035A1 (en) | 2005-10-06 | 2007-04-12 | New York Blood Center, Inc. | Anti-infective hygiene products based on cellulose acetate phthalate |
BRPI0808052A2 (en) * | 2007-02-28 | 2014-06-24 | Mead Johnson Nutrition Co | METHOD TO TREAT OR PREVENT SYSTEMIC INFLAMMATION. |
PL210465B1 (en) | 2007-06-04 | 2012-01-31 | Inst Biotechnologii Surowic I Szczepionek Biomed Społka Akcyjna | Composition of strains type Lactobacillus and application of the composition of strains type Lactobacillus |
US20110064706A1 (en) * | 2008-01-11 | 2011-03-17 | U.S. Nutraceuticals, Llc D/B/A Valensa International | Method of preventing, controlling and ameliorating urinary tract infections and supporting digestive health by using a synergistic cranberry derivative, a d-mannose composition and a proprietary probiotic blend |
US20090226548A1 (en) * | 2008-01-11 | 2009-09-10 | U.S. Nutraceuticals, Llc D/B/A Valensa International | Method of preventing, controlling and ameliorating urinary tract infections using a synergistic cranberry derivative and d-mannose composition |
AU2009314666B2 (en) | 2008-11-17 | 2015-01-29 | Winclove Holding B.V. | Pharmaceutical preparation comprising a combination of Streptococcus strains and Lactobacillus strains |
EP2206506A1 (en) * | 2008-12-18 | 2010-07-14 | Bracco Imaging S.p.A | Probiotic formulations |
US20120128645A1 (en) * | 2009-07-16 | 2012-05-24 | Hiroshima University | Prophylactic, ameliorating or therapeutic agent for oral diseases |
US10104903B2 (en) | 2009-07-31 | 2018-10-23 | Mars, Incorporated | Animal food and its appearance |
US9138441B2 (en) | 2009-12-31 | 2015-09-22 | Ira Milton Trachtman | Compositions and method for treatment and prophylaxis of inflammatory bowel disease |
CN103124559B (en) | 2010-08-04 | 2017-03-29 | 托马斯·朱利叶斯·波洛迪 | Compositions for fecal flora implantation, methods of making and using the same, and devices for delivering the same |
EP2428214A1 (en) | 2010-09-14 | 2012-03-14 | HSO Health Care GmbH | Compositions for the vaginal and oral administration of lactobacillus and uses thereof |
EE05750B1 (en) * | 2011-02-25 | 2015-06-15 | OÜ Tervisliku Piima Biotehnoloogiate Arenduskeskus | Isolated microorganism strain Lactobacillus gasseri MCC2 DSM 23882 and its use |
CN111518866A (en) | 2011-03-01 | 2020-08-11 | 群体创新有限责任公司 | Materials and methods for treating conditions associated with pathogenic biofilms |
AU2012225305B2 (en) | 2011-03-09 | 2017-06-08 | Regents Of The University Of Minnesota | Compositions and methods for transplantation of colon microbiota |
WO2012122472A1 (en) | 2011-03-09 | 2012-09-13 | Northwestern University | Compositions and methods for treatment of pain |
ITMI20110793A1 (en) | 2011-05-09 | 2012-11-10 | Probiotical Spa | STRAINS OF PROBIOTIC BACTERIA AND SYNBIOTIC COMPOSITION CONTAINING THEMSELVES INTENDED FOR THE BABY FOOD. |
ITMI20110791A1 (en) | 2011-05-09 | 2012-11-10 | Probiotical Spa | BACTERIA OF BACTERIA ABLE TO METABOLIZE THE OXALATES. |
ITMI20110792A1 (en) | 2011-05-09 | 2012-11-10 | Probiotical Spa | STRAINS OF BACTERIA BELONGING TO THE BIFIDOBACTERIUM TYPE FOR USE IN THE TREATMENT OF HYPERCOLESTEROLEMIA. |
ITMI20111718A1 (en) | 2011-09-23 | 2013-03-24 | Probiotical Spa | A WATERPROOF MOISTURE AND OXYGEN MATERIAL FOR PACKAGING DIETARY, COSMETIC AND MEDICINAL PRODUCTS. |
KR101287126B1 (en) * | 2011-10-28 | 2013-07-17 | 대상에프앤에프 주식회사 | Pharmaceutical compositon prevention and treatment of vaginitis and urinary tract infection comprising fermented solution of plant-originated Lactic acid bacteria |
CN104780932A (en) | 2012-02-29 | 2015-07-15 | 伊西康内外科公司 | Compositions of microbiota and methods related thereto |
EP2830599B1 (en) | 2012-03-29 | 2018-08-15 | Therabiome, Llc | Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix |
CN104540934A (en) | 2012-04-05 | 2015-04-22 | 热尔韦·达诺尼公司 | Lactobacillus rhamnosus food grade bacteria |
FR2992973B1 (en) | 2012-07-09 | 2015-12-18 | S P M D | NEW STRAIN OF LACTOBACILLUS CRISPATUS |
FR2992861B1 (en) | 2012-07-09 | 2014-10-17 | Probionov | USE OF THIOSULFATE FOR POTENTIATING THE ANTI-PATHOGENIC EFFECT OF LACTOBACILLES |
US20150374764A1 (en) * | 2013-02-07 | 2015-12-31 | Organobalance Gmbh | Composition comprising lactobacillus and a carrier |
CA2904389C (en) | 2013-03-14 | 2018-09-18 | Jerome J. Schentag | Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents |
ITMI20130794A1 (en) * | 2013-05-14 | 2014-11-15 | Probiotical Spa | COMPOSITION INCLUDING LACTIC BACTERIA FOR USE IN THE PREVENTIVE AND CURATIVE TREATMENT OF BACTERIAL VAGINOSIS. |
ITMI20130793A1 (en) | 2013-05-14 | 2014-11-15 | Probiotical Spa | COMPOSITION INCLUDING LACTIC BACTERIA FOR USE IN THE PREVENTIVE AND / OR CURATIVE TREATMENT OF THE RECURRENT CYCLES. |
CA2964480A1 (en) | 2014-10-31 | 2016-05-06 | Whole Biome Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
EP3064072A1 (en) * | 2015-02-11 | 2016-09-07 | AB-Biotics S.A. | Probiotic lactobacillus strains for use in treating urinary tract infections |
MX2017013715A (en) | 2015-04-28 | 2018-03-02 | Mars Inc | Process of preparing a sterilized wet pet food product. |
AU2016259871B2 (en) | 2015-05-11 | 2020-04-16 | Mybiotics Pharma Ltd | Systems and methods for growing a biofilm of probiotic bacteria on solid particles for colonization of bacteria in the gut |
BR112017024777A2 (en) | 2015-05-22 | 2018-08-07 | Univ Arizona State | use of a pharmaceutical composition and a non-absorbable antibiotic for treating autistic spectrum disorder cross reference to related applications? |
AU2016287200B2 (en) * | 2015-06-29 | 2020-09-17 | Ferring B.V. | Lactobacillus rhamnosus bacterium for treatment of e.g. bacterial vaginosis |
FR3048361B1 (en) | 2016-03-01 | 2020-12-18 | Biose | COMPOSITIONS FOR THE TREATMENT OF CANDIDOSES |
IL294171A (en) | 2016-05-25 | 2022-08-01 | Mybiotics Pharma Ltd | Composition and methods for microbiota therapy |
US20170360848A1 (en) | 2016-06-15 | 2017-12-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods for treating autism spectrum disorder and associated symptoms |
US20180036352A1 (en) | 2016-08-03 | 2018-02-08 | Crestovo Holdings Llc | Methods for treating ulcerative colitis |
AU2017327504B2 (en) * | 2016-09-16 | 2024-08-22 | International N&H Denmark Aps | Bacteria |
US10092601B2 (en) | 2016-10-11 | 2018-10-09 | Crestovo Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
US11213549B2 (en) | 2016-10-11 | 2022-01-04 | Finch Therapeutics Holdings Llc | Compositions and method for treating primary sclerosing cholangitis and related disorders |
US11026978B2 (en) | 2016-10-11 | 2021-06-08 | Finch Therapeutics Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
AU2018250206A1 (en) | 2017-04-05 | 2019-10-31 | Crestovo Holdings Llc | Compositions and methods for treating parkinson's disease (PD) and related disorders |
WO2018187464A1 (en) | 2017-04-05 | 2018-10-11 | Crestovo Holdings Llc | Compositions and methods for treating diverticulitis and related disorders |
WO2018218159A1 (en) | 2017-05-26 | 2018-11-29 | Crestovo Holdings Llc | Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same |
CN111328284A (en) | 2017-08-07 | 2020-06-23 | 芬奇治疗公司 | Compositions and methods for maintaining and restoring a healthy intestinal barrier |
AU2018326705A1 (en) | 2017-08-30 | 2020-03-05 | Pendulum Therapeutics, Inc. | Methods and compositions for treatment of microbiome-associated disorders |
US11166990B2 (en) | 2018-07-13 | 2021-11-09 | Finch Therapeutics Holdings Llc | Methods and compositions for treating ulcerative colitis |
US11911419B2 (en) | 2018-09-27 | 2024-02-27 | Finch Therapeutics Holdings Llc | Compositions and methods for treating epilepsy and related disorders |
US20210268046A1 (en) * | 2020-02-18 | 2021-09-02 | HoneyHills TX, LLC | Cannabinoid & probiotic suppositories & methods of use |
US20230323332A1 (en) | 2020-08-28 | 2023-10-12 | Chr. Hansen A/S | Microencapsulation of microbial culture using octenyl succinic anhydride starch-chitosan complex coacervate |
CN112708583B (en) * | 2021-01-29 | 2022-05-17 | 重庆第二师范学院 | Lactobacillus fermentum LF-SCHY34 and application thereof |
KR102337951B1 (en) * | 2021-06-25 | 2021-12-13 | 주식회사 비피도 | Lactobacillus helveticus GUT10 for improvement, prevention or treatment of urinary tract infection and composition comprising the same |
WO2024184258A1 (en) | 2023-03-03 | 2024-09-12 | Chr. Hansen A/S | Compositions comprising lactobacillus reuteri, lactobacillus rhamnosus, and 2'-fucosyllactose |
CN118360221B (en) * | 2024-06-19 | 2024-09-13 | 南昌大学 | Lactobacillus crispatus NCU-23 and application thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE469875C (en) | 1991-07-25 | 1997-04-14 | Probi Ab | Strain of intestinal colonizing Lactobacillus and composition for prophylaxis or treatment of gastrointestinal infections |
GB2261372A (en) * | 1991-11-15 | 1993-05-19 | Gregor Reid | Lactobacillus and skim milk compositions for prevention of urogenital infection |
US5733568A (en) * | 1993-12-03 | 1998-03-31 | Lafor Laboratories Limited | Micro-encapsulated lactobacilli for medical applications |
US6180100B1 (en) * | 1994-09-30 | 2001-01-30 | Urex Biotech., Inc. | Lactobacillus compositions and methods for treating urinary tract infections |
US6051552A (en) * | 1996-05-30 | 2000-04-18 | Urex Biotech, Inc. | Lactobacillus therapies |
EP2159277A1 (en) | 1996-11-29 | 2010-03-03 | Bio-K Plus International, Inc. | Lactic ferment comprising a particular strain of lactobacillus acidophillus and use thereof |
-
1999
- 1999-12-10 WO PCT/CA1999/001182 patent/WO2000035465A2/en not_active Application Discontinuation
- 1999-12-10 DE DE69924141T patent/DE69924141D1/en not_active Expired - Lifetime
- 1999-12-10 EP EP99957817A patent/EP1137423B1/en not_active Expired - Lifetime
- 1999-12-10 ID IDW00200101506A patent/ID30071A/en unknown
- 1999-12-10 KR KR1020017007267A patent/KR20010101171A/en not_active Application Discontinuation
- 1999-12-10 AU AU15434/00A patent/AU1543400A/en not_active Abandoned
- 1999-12-10 JP JP2000587784A patent/JP2003522731A/en active Pending
- 1999-12-10 NZ NZ512275A patent/NZ512275A/en not_active IP Right Cessation
- 1999-12-10 AT AT99957817T patent/ATE290391T1/en not_active IP Right Cessation
- 1999-12-10 US US09/459,292 patent/US6479051B1/en not_active Expired - Lifetime
- 1999-12-10 IL IL14363299A patent/IL143632A0/en unknown
- 1999-12-10 TR TR2001/01699T patent/TR200101699T2/en unknown
- 1999-12-10 BR BR9916062-5A patent/BR9916062A/en not_active Application Discontinuation
- 1999-12-10 CA CA2354054A patent/CA2354054C/en not_active Expired - Lifetime
- 1999-12-10 PL PL99348973A patent/PL348973A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2000035465A3 (en) | 2000-12-28 |
CA2354054C (en) | 2011-04-12 |
WO2000035465A2 (en) | 2000-06-22 |
JP2003522731A (en) | 2003-07-29 |
KR20010101171A (en) | 2001-11-14 |
US6479051B1 (en) | 2002-11-12 |
TR200101699T2 (en) | 2002-06-21 |
AU1543400A (en) | 2000-07-03 |
PL348973A1 (en) | 2002-06-17 |
EP1137423B1 (en) | 2005-03-09 |
ATE290391T1 (en) | 2005-03-15 |
CA2354054A1 (en) | 2000-06-22 |
NZ512275A (en) | 2003-11-28 |
DE69924141D1 (en) | 2005-04-14 |
ID30071A (en) | 2001-11-01 |
EP1137423A2 (en) | 2001-10-04 |
BR9916062A (en) | 2002-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL143632A0 (en) | Pharmaceutical compositions containing lactobacillus | |
WO2000071138A3 (en) | Oral administration of lactobacillus for the maintenance of health in women | |
GR3026758T3 (en) | Lactobacillus strains of human origin, their compositions and uses thereof | |
NZ516020A (en) | Dietary or pharmaceutical composition for use for the prevention or treatment of hyperoxaluria | |
IL156490A0 (en) | Probiotic compounds derived from lactobacillus casei strain ke01 | |
MY116272A (en) | Immunity enhancing lactic acid bacteria | |
CA2292706A1 (en) | Method for administering viable microorganism composition for poultry | |
TNSN99254A1 (en) | BEVERAGES CONTAINING LIVE LACTIC BACTERIA | |
HUP0402460A2 (en) | New strain of lactic acid bacterium and edible compositions, drugs and veterinary products containing it | |
EP1498039A4 (en) | Vital cell preparations containing lactic acid bacterium as the active ingredient and lactic acid bacterium-containing foods | |
HK1046929A1 (en) | Bifidobacteria preventing diarrhea caused by pathogenic bacteria | |
WO2003039260A3 (en) | Probiotic compositions | |
AP1563A (en) | Lactic acid bacteria for the treatment and /or prophylaxis of giardiasis. | |
PT1353681E (en) | Bifidobacteria capable of preventing diarrhea | |
CA2294670A1 (en) | Composition suitable as food integrator and for the treatment of intestinal disorders and alterations of the bacterial flora | |
EE200300220A (en) | Method for screening probiotic strains of the Bifidobacterium family | |
MD20010055A (en) | Microbial sanogenic preparation for prevention and treatment of intestinal disbacteriosis | |
UA30798A (en) | Method of oncology patients prolonged therapy | |
MD2527C2 (en) | Association of Bifidobacterium longum var. animalis and Lactobacillus acidophilus strains - producers of vitamins B1, B2 and B3 | |
UA41491C2 (en) | Healthful and dietary fermented milk product |